A Controversial Suspension: Profar's PED Journey
The baseball world is abuzz with the news of Jurickson Profar's second PED suspension, this time facing a staggering 162-game ban. ESPN's Jeff Passan broke the story, revealing Profar's impending absence from the entire 2026 season. But here's where it gets controversial: Profar's first suspension, which cost him 80 games last season, already had a significant impact on his career and earnings.
Profar, now 33, signed a three-year, $42 million contract, but his first suspension resulted in a loss of nearly $6 million from his $12 million salary in the first year. With this second suspension, he not only misses out on his $15 million salary for the upcoming season but also becomes ineligible for the World Baseball Classic and any postseason play in 2026. If he tests positive again, he faces a lifetime ban.
A Promising Career Derailed
Profar's journey is a cautionary tale. As a teenager, he was ranked as the top prospect in baseball, a switch-hitting shortstop with an impressive blend of power, speed, and defensive skills. However, multiple shoulder injuries derailed his career. He underwent surgery, missing nearly the entire 2014 and 2015 seasons. When he returned, his game had changed; his batting average dropped, and his defense at shortstop became a liability.
Profar's career took him to various teams, including the A's and Padres, with mixed results. He had a solid offensive season in 2018 but struggled in San Diego, especially in the shortened 2020 season. Free agency was challenging for Profar, and he signed a $7.75 million deal with the Rockies, only to be released after a disappointing performance.
The Braves' Decision
Profar's impressive showing with the Padres in 2023, where he hit .280/.380/.459, led the Braves to sign him to a three-year, $42 million contract. However, with this suspension, Profar won't take the field again until at least 2027. The Braves have the option to place him on the restricted list, saving them $15 million in salary and dodging the 20% tax they've been paying as a luxury tax threshold team. This amounts to a significant $18 million in savings for Atlanta.
The Braves' rotation has also been hit with injuries, with right-handers Spencer Schwellenbach and Hurston Waldrep undergoing elbow surgeries. This leaves the team with a top four rotation of Chris Sale, Spencer Strider, Reynaldo Lopez, and Grant Holmes. The fifth starter options include Bryce Elder, Joey Wentz, Didier Fuentes, and Jose Suarez.
Implications and Opportunities
With the savings from Profar's suspension and the influx of cash, the Braves now have intriguing possibilities. They could use these funds to acquire additional help, such as another starting pitcher or a veteran right-handed batter. Atlanta's outfield group takes a hit with Profar's suspension, but the team's recent signing of Mike Yastrzemski provides some depth. Yastrzemski, along with Michael Harris II and Ronald Acuña Jr., can start most days, but Acuña's recent injury troubles and Yastrzemski's platoon issues are factors to consider.
The Braves' front office now has a decision to make: Will they use these funds immediately to strengthen the team, or will they save for in-season additions? Either way, Atlanta has become a team to watch, and the baseball community eagerly awaits their next move.
And this is the part most people miss: Profar's story is a reminder of the impact of PED suspensions on players' careers and the complex decisions teams must make in response. What do you think? Should the Braves use their newfound funds to make immediate roster changes, or is it wiser to save for the future? Share your thoughts in the comments!
